RxDoctor Payments Data

Janet Zarzour

Family · Cleveland, TNNPI 1003362633

Payments from drug & device makers

$1,769in general payments, 2019–2025

Across 35 payments — averaging $50.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$314
  • Neurocrine Biosciences, Inc.$258
  • Acadia Pharmaceuticals Inc$250
  • Otsuka America Pharmaceutical, Inc.$223
  • AbbVie$202
  • Corium, LLC$141
  • plus $382 from 7 others

What the payments were for

  • Food & beverage$1,769100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,769 in reported general payments places this provider in the 75th percentile of 6,706 family providers in Tennessee.

See all family providers in Tennessee

Medicare billing

Part B allowed, 2024
$196,745
Medicare patients
518
Services billed
2,114

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate13$114,848
Invega SustennaPaliperidone Palmitate32$72,369
NuplazidPimavanserin Tartrate20$69,311
Lurasidone Hcl67$23,619
Chlorpromazine Hcl13$16,033
Divalproex Sodium493$14,041
Quetiapine Fumarate729$9,789
Divalproex Sodium ErDivalproex Sodium166$6,580
Paliperidone ErPaliperidone13$6,553
Buspirone Hcl785$6,025
Carbamazepine ErCarbamazepine35$4,281
Aripiprazole116$4,238
Sertraline Hcl569$3,429
Trazodone Hcl481$3,221
Fluphenazine Hcl13$3,180

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$258$114,84813 claims
Johnson & JohnsonInvega Sustenna$65$72,36932 claims
Acadia Pharmaceuticals IncNuplazid$250$69,31120 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 6,706 family providers in Tennessee.

Other family in Cleveland

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →